Skip to content

Research at St Andrews

Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells

Research output: Contribution to journalArticle

Author(s)

Falko Hochgraefe, Luxi Zhang, Sandra A. O'Toole, Brigid C. Browne, Mark Pinese, Ana Porta Cubas, Gillian M. Lehrbach, David R. Croucher, Danny Rickwood, Alice Boulghourjian, Robert Shearer, Radhika Nair, Alexander Swarbrick, Dana Faratian, Peter Mullen, David J. Harrison, Andrew V. Biankin, Robert L. Sutherland, Mark J. Raftery, Roger J. Daly

School/Research organisations

Abstract

To identify therapeutic targets and prognostic markers for basal breast cancers, breast cancer cell lines were subjected to mass spectrometry-based profiling of protein tyrosine phosphorylation events. This revealed that luminal and basal breast cancer cells exhibit distinct tyrosine phosphorylation signatures that depend on pathway activation as well as protein expression. Basal breast cancer cells are characterized by elevated tyrosine phosphorylation of Met, Lyn, EphA2, epidermal growth factor receptor (EGFR), and FAK, and Src family kinase (SFK) substrates such as p130Cas. SFKs exert a prominent role in these cells, phosphorylating key regulators of adhesion and migration and promoting tyrosine phosphorylation of the receptor tyrosine kinases EGFR and Met. Consistent with these observations, SFK inhibition attenuated cellular proliferation, survival, and motility. Basal breast cancer cell lines exhibited differential responsiveness to small molecule inhibitors of EGFR and Met that correlated with the degree of target phosphorylation, and reflecting kinase coactivation, inhibiting two types of activated network kinase (e. g., EGFR and SFKs) was more effective than single agent approaches. FAK signaling enhanced both proliferation and invasion, and Lyn was identified as a proinvasive component of the network that is associated with a basal phenotype and poor prognosis in patients with breast cancer. These studies highlight multiple kinases and substrates for further evaluation as therapeutic targets and biomarkers. However, they also indicate that patient stratification based on expression/activation of drug targets, coupled with use of multi-kinase inhibitors or combination therapies, may be required for effective treatment of this breast cancer subgroup. Cancer Res; 70(22); 9391-401. (C) 2010 AACR.

Close

Details

Original languageEnglish
Pages (from-to)9391-9401
Number of pages11
JournalCancer Research
Volume70
Issue number22
DOIs
Publication statusPublished - 15 Nov 2010

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031

    Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In : Scientific Reports. 9, 13 p., 7643.

    Research output: Contribution to journalArticle

  2. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

    Lubbock, A. L. R., Stewart, G. D., O'Mahoney, F. C., Laird, A., Mullen, P., O'Donnell, M., Powles, T., Harrison, D. J. & Overton, I. M., 26 Jun 2017, In : BMC Medicine. 15, 12 p., 118.

    Research output: Contribution to journalArticle

  3. A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT

    Brown, J. L., Shovman, M., Robertson, P., Boiko, A., Goltsov, A., Mullen, P. & Harrison, D. J., May 2017, In : Oncotarget. 8, 18, p. 29657-29667 11 p.

    Research output: Contribution to journalArticle

  4. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

    Meehan, J., Ward, C., Turnbull, A., Bukowski-Wills, J., Finch, A., Jarman, E. J., Xintaropoulou, C., Martinez-Perez, C., Gray, M., Pearson, M., Mullen, P., Supuran, C. T., Carta, F., Harrison, D. J., Kunkler, I. H. & Langdon, S., 2017, In : Oncotarget. 8, 26, p. 42857-42875

    Research output: Contribution to journalArticle

  5. Total synthesis of dehaloperophoramidine using a highly diastereoselective Hosomi-Sakurai reaction

    Wilkie, R. P., Neal, A., Johnston, C. A., Voûte, N., Lancefield, C. S., Stell, M., Medda, F., Makiyi, E. F., Turner, E., Ojo, O. S., Slawin, A. M. Z., Lebl, T., Mullen, P., Harrison, D. J., Ireland, C. M. & Westwood, N. J., 14 Sep 2016, In : Chemical Communications. 52, 71, p. 10747-10750

    Research output: Contribution to journalArticle

Related by journal

  1. Correction: Physical oncology: A bench-to-bedside quantitative and predictive approach

    Frieboes, H. B., Chaplain, M. A. J., Thompson, A. M., Bearer, E. L., Lowengrub, J. S. & Cristini, V., 1 Mar 2011, In : Cancer Research. 71, 5, p. 2024 1 p.

    Research output: Contribution to journalArticle

  2. Physical oncology: a bench-to-bedside quantitative and predictive approach

    Frieboes, H. B., Chaplain, M. A. J., Thompson, A. M., Bearer, E. L., Lowengrub, J. S. & Cristini, V., 15 Jan 2011, In : Cancer Research. 71, 2, p. 298-302 5 p.

    Research output: Contribution to journalArticle

  3. Quantifying the role of angiogenesis in malignant progression of gliomas: In Silico modeling integrates imaging and histology

    Swanson, K. R., Rockne, R. C., Alvord Jr., E. C., Claridge, J., Chaplain, M. A. & Anderson, A. R. A., 2011, In : Cancer Research. 71, 24, p. 7366-7375 10 p.

    Research output: Contribution to journalArticle

  4. Effects of letrozole and anastrozole on low ER expressing invasive breast carcinomas: results from a randomised trial

    Foratian, D., Renshaw, L., Caldwell, H., Williams, L., Murray, J., Young, O., Evans, D. B., Thomas, J. S., Harrison, D. J. & Dixon, J. M., 15 Jan 2009, In : Cancer Research. 69, 2, p. 125S-125S 1 p.

    Research output: Contribution to journalAbstract

ID: 23160219

Top